Full text is available at the source.
Abstract
Psilocybin therapy for treatment-resistant depression (TRD) is being examined for its antidepressant outcomes and safety in real-world settings.
- Preliminary findings suggest psilocybin may have antidepressant effects in individuals with TRD.
- The study investigates the safety of psilocybin therapy, which remains largely unknown in therapeutic contexts.
- Feasibility of conducting psilocybin therapy with repeated dosing sessions is being assessed.
- Psilocybin is currently not approved as an antidepressant but is permitted for limited medical use in Switzerland.
Simplified
Psychedelic Science